CUSTOMER SUPPORT
Need help? Have a question or a suggestion?
Feel free to compare
Quality is of utmost importance when you select a provider for genetic testing and we are confident that deCODEme is exceptional when compared to rival products. Our customers benefit directly from the expertise of scientists at deCODE Genetics, a company with an unparalleled track record in gene discovery for common diseases. We leverage our scientific skills and experience with high-throughput genotyping when we design our genetic scans.
More SNPs analyzed for better results
We strive to make our genetic scans as comprehensive and reliable as possible. Thus, for any given disease, we measure all the most important genetic risk variants (SNPs) that are supported by solid scientific evidence. To accomplish this, we not only use the best chip genotyping technology available, but also other methods to pick up key variants that were not included in the chip design. All of the measurements are carried out in our own CLIA certified laboratories. This ensures a very fast turn around time for your results and allows deCODEme products to stay in tune with the latest discoveries in genetic research.
The best genome coverage
Our complete scan is based on a chip with approximately 1.2 million SNPs. This means that our measurements cover your genome with a higher density of SNPs than any of our competitors. Hence, the accuracy in your ancestry analysis and genome comparison with friends is greater with deCODEme. Likewise, by choosing our complete scan you can benefit from future discoveries in human genetics because the new risk SNPs will very likely be discovered with SNPs that are already on the million chip or in close relationship to them.
Better coverage of different ethnicities
In the past, most research in human genetics has focused on people from North America and Western Europe. However our aim is to provide the best information regardless of ethnicity. We provide better coverage of SNPs associated with the most important diseases for all ethnicities.
Better SNP coverage in cardiovascular and cancer diseases*
The tables below compares the number of SNPs that are used in our deCODEme Complete Scan and our competition.
| Cancer Conditions | deCODEme | 23andMe | Navigenics |
|---|---|---|---|
| Prostate Cancer | 25 | 5 | 9 |
| Breast Cancer | 11 | 2 | 7 |
| Lung Cancer | 2 | 1 | 1 |
| Bladder Cancer | 4 | 2 | 0 |
| Basal Cell Cancer | 6 | 2 | 0 |
| Colorectal Cancer | 8 | 3 | 5 |
| Melanoma | 0 | 1 | 0 |
| Chronic Lymphocytic Leukemia | 6 | 6 | 2 |
| Thyroid Cancer | 2 | 1 | 0 |
| Brain Cancer-Glioma | 4 | 0 | 0 |
| Ovarian Cancer | 1 | 0 | 0 |
| Testicular Cancer | 3 | 0 | 0 |
| Total: | 72 | 23 | 24 |
| Cardiovascular Conditions | deCODEme | 23andMe | Navigenics |
|---|---|---|---|
| Heart Attack (Myocardial Infarction) | 8 | 1 | 2 |
| Atrial Fibrillation | 3 | 2 | 2 |
| Abdominal Aortic Aneurysm | 1 | 1 | 1 |
| Intracranial Aneurysm | 3 | 1 | 1 |
| Peripheral Arterial Disease | 1 | 1 | 0 |
| Venous Thromboembolism | 1 | 2 | 0 |
| Total: | 17 | 8 | 6 |
* Data as of Sept 29th, 2009. The table and the figures above compare variants included in the deCODEme Complete Scan discovered through scientific research in which participants are of European ancestry. deCODEme only reports on variants found through genome wide association studies which have also been replicated in an independent population or cohorts. 23andMe and Navigenics are trademarks of 23andMe, Inc. and Navigenics, Inc. respectively.